Overview

AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Status:
Recruiting

Trial end date:
2024-06-27

Target enrollment:

Participant gender:

Summary

At least one dose level of AMG 176 will achieve acceptable safety and tolerability in subjects with relapsed or refractory multiple myeloma and subjects with relapsed or refractory acute myeloid leukemia

Phase:

Phase 1

Details

Lead Sponsor:

Amgen

Treatments:

Azacitidine
Itraconazole